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Abstract: 
Current vascular replacement grafts used in congenital heart defect 
corrective surgery have poor longevity and growth potential. Recipient 
patients often require multiple reoperations. Tissue engineering has the 
promise to produce a graft with the potential to grow, remodel and repair. 
Here we aimed at developing an amnion-based scaffold suitable for 
cardiovascular tissue engineering applications and in vivo usage. The 
developed human amnion-based scaffold was made by an enzymatic 
decellularization process followed by freeze-drying as a single or multi-
layered structure. These structures were compared to native amnion for 
seeded cell viability and biomechanical properties then tested for in vivo 
biocompatibility. Our results demonstrated that while native amnion tissue 
supported little cell growth, the decellularized-amnion allowed cell 
engraftment and survival. Additionally, preservation of the scaffold by 
freeze-drying as a single layer, allowed cell engraftment and growth. Multi-
layering the freeze-dried amnion-scaffolds resulted in a similar cell growth 
potential of the single layered construct but superior mechanical strength. 
The multi-layered construct showed in vitro biocompatibility with 
endothelial cells, smooth muscle cells, cardiac myocytes, and thymus and 
cord-blood-derived MSCs. When implanted in a piglet model of left 
pulmonary artery grafting, the multi-layered construct showed its in vivo 
suitability and biocompatibility for vascular repair as demonstrated by the 
development of newly formed endothelium in the intima, a smooth muscle 
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cell-rich medial layer and an adventitia containing new vasa vasorum. In 
conclusion, our developed amnion-derived scaffold represents an off-the-
shelf biocompatible structure that can be seeded with the patient’s own 
MSCs to produce an autologous vascular graft. 
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ABSTRACT 
Current vascular replacement grafts used in congenital heart defect corrective surgery have poor 
longevity and growth potential. Recipient patients often require multiple reoperations. Tissue 
engineering has the promise to produce a graft with the potential to grow, remodel and repair. Here we 
aimed at developing an amnion-based scaffold suitable for cardiovascular tissue engineering 
applications and in vivo usage. The developed human amnion-based scaffold was made by an enzymatic 
decellularization process followed by freeze-drying as a single or multi-layered structure. These 
structures were compared to native amnion for seeded cell viability and biomechanical properties then 
tested for in vivo biocompatibility. Our results demonstrated that while native amnion tissue supported 
little cell growth, the decellularized-amnion allowed cell engraftment and proliferation cell survival. 
Additionally, preservation of the scaffold by freeze-drying as a single layer, allowed further improved cell 
engraftment and cell growth. Multi-layering the freeze-dried amnion-scaffolds resulted in a similar cell 
growth potential of the single layered construct but superior mechanical strength. The multi-layered 
construct showed in vitro biocompatibility with endothelial cells, smooth muscle cells, cardiac myocytes, 
and thymus and cord-blood-derived MSCs. When implanted in a piglet model of left pulmonary artery 
grafting, the multi-layered construct showed its in vivo suitability and biocompatibility for vascular 
repair as demonstrated by the development of newly formed endothelium in the intima, a smooth 
muscle cell-rich medial layer and an adventitia containing new vasa vasorum.  endothelial cell layer in 
the inner side of the graft and a smooth muscle layer in the outer side. In conclusion, our developed 
amnion-derived scaffold represents an off-the-shelf biocompatible structure that can be seeded with 
the patient’s own MSCs to produce an autologous vascular graft. 
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Amnion, Tissue Engineering, Decellularization, Mesenchymal Stem Cells, Corrective Heart Surgery. 
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Impact statement 
This study aimed at developing an amnion-based scaffold suitable for vascular tissue engineering 
applications and in vivo usage. We successfully produced a multi-layered scaffold with improved 
biomechanical properties and biocompatibility for in vivo vascular implantation. Our approach, not only, 
offers an allogeneic ‘off-the-shelf’ solution for clinical use, but it also provides the possibility of 
personalized medicine by using a patient’s own amnion and stem cells for the production of a tissue 
engineered grafts for reconstructive heart surgery. 
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INTRODUCTION 
Congenital heart disease (CHD) is characterized as a heart, aortic, or large blood vessel 
malformation. Each year, more than one million children worldwide are affected [1], [2]. More than 40 
different types of defects have been described, ranging from common, ventricular septal defects (VSD) 
to the severe tetralogy of Fallot [1], [3]. In the most severe cases, surgery is the only therapeutic option, 
especially as tissu  for transplantations are rare. These surgeries involve using allografts, xenografts, or 
synthetics to create new conduits and patches in the heart. Allografts and xenografts are the current 
clinical standard but, like synthetics, they lack longevity, especially when implanted in immature hearts 
[4]. All these materials do not grow, repair, or remodel with the patient requiring multiple surgeries 
throughout their lifetime [5].  
Tissue engineering offers an alternative source of implants by combining a biofunctional scaffold with 
allogeneic or autologous stem cells. An ideal scaffold would be nonimmunogenic, nonthrombotic, 
biocompatible, and have growth and remodeling potential [6]. This scaffold should also have a durable 
extracellular matrix that can survive in vivo blood pressures. Human amniotic membrane offers a 
potential scaffold as it is an easily obtainable biologic material that has been used for over a century in 
skin repair and burn treatment [7], [8]. Later, it was employed for conjunctiva repair [9]. It has been 
tested in animal models for urethra repair, ocular surface reconstruction, liver repair, and pericardial 
closure [10]–[13]. In human patients, it has been used for lower eyelid repair, fistula closures, and 
neovagina construction [14]–[16]. Additionally, it has been shown that amnion has anti-inflammatory 
and anti-microbial properties [17]–[21]. 
 Bio-functional extracellular matrix is critical in a scaffold for it to be effective in tissue 
engineering. Studies have demonstrated that the amnion’s extracellular matrix is primarily composed of 
collagen, which is conducive to wound healing, as well as fibronectin, proteoglycans, laminins, and 
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glycosamnioglycans [17], [22], [23]. Although in most studies the amnion have been used without much 
modification other than dehydration, several investigations have decellularized it beforehand using a 
range of approaches including freeze-thawing[24], [25], EDTA[26], and trypsin-EDTA treatment[12], [13]. 
The latter method retained structural matrix proteins such as collagen type I and IV, fibronectin, and 
laminin[12], [27]. Many studies have demonstrated successful seeding of decellularized amnion 
scaffolds with diff rentiated cells such as human dermal fibroblasts[28], human corneal fibroblasts[25], 
and smooth muscle cells[24]. Fewer investigations have been carried out to recellularize amnion with 
stem cells, an approach that could be more promising for tissue engineering purposes.  
Long-term amnion preservation is essential for tissue engineering. While matrix preservation was not 
considered or attempted in many studies [24]–[26], the beneficial effects of preservation were 
demonstrated by others[28]. Reported preservation work utilized different methods including 
dehydration[13], [28], refrigeration or freezing[12]. The latter approach resulted in ice crystal formation, 
contamination, or extracellular matrix protein damage.  
In addition to scaffolds, cells represent the second c mponent needed for tissue engineering. 
Mesenchymal stem cells (MSCs) have been isolated from multiple sources such as bone marrow and 
adipose tissue [29]. Critically for congenital heart defect repair, MSCs have also been isolated from cord 
blood and thymus tissue [30]–[32]. MSCs are promising for seeding onto scaffolds as part of a tissue 
engineered construct for cardiac repair because of their multilineage differentiation potential, ability to 
regulate the immune response, and because they do not cause teratomas [33]–[35].  
 Here, we combined a decellularization and freeze-drying approach to produce an amnion based 
scaffold suitable for tissue engineering constructs destined for reconstructive heart surgery application. 
Our data showed in vitro and in vivo biocompatibility of the developed amnion-based construct and its 
suitability for use in pulmonary artery position. Our developed preserved construct offers an ‘off-the-
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shelf’ solution for allogeneic clinical use. Furthermore, it represents a key component for personalized 
medicine, which is possible by using a patient’s own amnion and stem cells for the construction of a 
tissue engineered graft.  
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MATERIALS AND METHODS 
Ethics 
Human tissue was collected from patients in compliance with the Human Tissue Act. Perinatal and 
leftover material (the thymus, cord blood, and placenta) were obtained with parents’ consent under 
NHS ethics license (REC ref. 06/Q2001/197 and 11/SW/0122).  
Amnion Preparation 
Amnion was collected from 25 human cesarean sections. Amnion (AM) was removed from the fetal side 
of the placenta by blunt dissection. It was washed once in PBS and then repeatedly with water. It was 
then stored overnight at 4oC in PBS.   
Amnion Decellularization 
AM was decellularized in 6-well crown inserts (Scaffdex). Crowns were placed in 0.1% trypsin in 10 mM 
Tris (Sigma) buffer pH 8.0 and incubated for 3 hours at 37oC under gentle rotation. The solution was 
changed to 500 U/mL DNase (Sigma) in 10 mM Tris buffer and incubated for an additional 3 hours at 
37oC under gentle rotation. Decellularized-AM (d-AM) was then washed in 10 mM Tris buffer every day 
for 5-9 days at 37oC under gentle rotation.  
Tissue Preservation 
AM and d-AM were preserved in single or multiple layers by removing from crowns and freezing at           
-20oC. For freezing, excess liquid was removed, and samples were laid completely flat. Multi-layer 
samples were stacked, cross-sectionally, on top of each other and all air bubbles were removed. They 
were then freeze-dried (fd; Edwards) and stored at room temperature. These single (d-AM-fd-single) 
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and multi-layered (d-AM-fd-multi) constructs were rehydrated in respective cell culture mediums prior 
in vitro testing.  
Thymus Derived Mesenchymal Stem Cells 
Thymus tissue was collected from patients undergoing congenital heart surgery and placed in sterile PBS 
from the surgical theatre. The thymus was washed in PBS (Life Technologies), minced into small pieces, 
and underwent a 2 hours collagenase I (Sigma-Aldrich, 0.3 mg/mL) enzymatic digestion. The digested 
tissue was forced through a strainer and was washed with fresh medium. The resulting cell suspension 
was centrifuged for 5 minutes at 420 x g at 22oC. The supernatant was discarded and cells were 
resuspended in Dulbecco's Modified Eagle Medium, low glucose (DMEM, Life Technologies) with 10% 
HyClone Fetal Bovine Serum (FBS, Thermo Scientific), 1% penicillin streptomycin (p/s, Life Technologies) 
on uncoated plastic, at approximately 1x106 cells/cm2 density in a 37oC humidified atmosphere with 5% 
CO2. After 72-96 hours, non-adherent cells were removed with two PBS washes. Adherent cells were 
cultured until confluence was reached, with feeding every 48-72 hours. At this point, cells were 
detached using Trypsin-EDTA (0.05%, Life Technologies) and then plated at approximately 1x104 
cells/cm2 in new flasks for next passage (P1).  
Umbilical Cord Blood Mesenchymal Stem Cells 
Human umbilical cord blood was collected in 1% herparin (LeoPharma) from consenting patients 
undergoing caesarean section. Blood was diluted 1:2 with P/S PBS and layered onto Ficoll (GE 
Healthcare). Tubes were centrifuged at 400 x g at room temperate for 30 minutes with no brake. 
Mononuclear cells were removed with a 10 mL syringe and washed three times with P/S PBS. Finally, 
they were spun at 420 x g for 5 minutes and the supernatant was discarded. Cells were plated at 
approximately 1x106 cells/cm2 on uncoated plastic and cultured in 95% air, 5% CO2, and 37oC. Non-
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adherent cells were removed by washing with PBS after 72-96 hours. Adherent cells were cultured with 
DMEM, 10% FBS, 1% P/S with media changes every 48-72 hours. 
Human Umbilical Vein Endothelial Cells 
Human umbilical cord vein (hUVEC) cells were purchased from Lonza. They were cultured on uncoated 
plastic in 95% air, 5% CO2, and 37oC in Endothelial Cell Growth Medium (PromoCell), with media changes 
every 48-72 hours.  
Cardiac Myocytes 
Cardiac Myocytes were purchases from PromoCell. They were cultured on uncoated plastic in 95% air, 
5% CO2, and 37oC in Cardiac Myocyte Growth Medium (PromoCell) according to manufacturer’s 
instructions.  
Arterial Smooth Muscle Cells 
Smooth muscle cells were collected from the artery of the umbilical cord. Cord was cut open, arteries 
were removed and cleaned in PBS, and chopped into pieces. Ar ery pieces were then cultured in DMEM, 
10% FBS, 1% P/S in 95% air, 5% CO2, and 37oC. Smooth muscle cells were outgrown from these arterial 
pieces in 10 cm petri dishes.  
AM cell seeding 
AM, d-AM, d-AM-fd-single and d-AM-fd-multi were sterilized under 295 nm UV for 30 minutes on each 
side. They were then seeded with each cell type at 250,000 cells/cm2 in respective culture mediums. 
Cell-seeded AM was cultured for 1 week at 37oC in a humidified atmosphere with 5% CO2 with medium 
changes every 2-3 days. Apart from hUVEC and cardiac myocytes (commercially sourced) a different cell 
line, prepared from a different sample, was used for each experimental point.  
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Cell Viability 
To test cell viability on scaffolds, the Live/Dead Viability/Cytotoxicity Kit, for mammalian cells 
(ThermoFisher) was used according to manufacturer’s instructions with Hoechst (ThermoFisher, 
1ng/mL) in PBS. Samples were imaged on a Zeiss Axio Observer.Z1 with Zen Blue software (Zeiss). Cell 
counts were performed using ImageJ.  
Immunohistochemistry 
For tissue analysis, samples were embedded in paraffin. First, they were fixed in 4% PFA, washed in PBS, 
moved in to cassettes (Histosette I, Symports), processed in a Thermo Excelsior AS, and embedded in a 
Thermo HistoStar machine. Sections were cut on a microtome (Thermo) at 5 µm, floated onto Menzel-
Glaser SuperFrost Plus slides (Thermo), and dried overnight. Hematoxylin and eosin (H&E) and van 
Gieson’s (EVG) stains were performed using a Shandon Varistain 24-4 (Thermo). Slides were removed 
from machine and mounted with DPX (distyrene, a plasticizer, in toluene-xylene; Sigma). Slides were 
imaged on a Zeiss Axio Observer.Z1 with Zen Blue software (Zeiss).  
For immunofluorescence analysis, samples were deparaffinized in clerene and rehydrated through an 
alcohol gradient. Antigen retrieval was performed with 10 mM citrate buffer pH 6.0 heated to boil. 10% 
goat serum (Sigma-Aldrich) in PBS was used to block the samples for 30 minutes at room temperature. 
Samples were incubated with the primary antibodies overnight at 4°C. Antibody solutions were 
prepared as follow: 1:100 Isolectin-B4-biotin (Life Technologies), 1:200 mouse to alpha-smooth muscle 
actin (Abcam), 1:100 mouse to smooth muscle-myosin heavy chain (Dako) and 1:100 rabbit to calponin 
(Dako). Secondary antibodies were then incubated on the sections for 1 hour at room temperature in 
the dark. The secondary antibodies used were as follow: 1:200 streptavidin-Alexa Flour 488 (Life 
Technologies), 1:300 goat-anti-mouse-Cy3 (Jackson Immuno Research Labs), 1:400 goat-anti-mouse-
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Alexa Flour 488 (Abcam) and 1:400 goat-anti-rabbit-Alexa Flour 546 (Abcam). Dapi was used to 
counterstain the nuclei and the slides were mounted using Hardset mounting medium (Vectashild). 
Scanning Electron Microscopy 
Tissue samples were prepared by fixing in 2.5% glutaraldehyde in sodium cacodylate buffer (Electron 
Microscopy Sciences) for 45 minutes. Following fixation, samples were washed 3 times in 0.1 M sodium 
cacodylate buffer (from Cacodylate acid, Sigma). Osmium (Electron Microscopy Sciences) solution was 
prepared with 1% osmium in 0.1 M sodium cacodylate buffer and put on samples for 20 minutes. 
Samples were washed and dehydrated as follows: three changes of 0.1 M sodium cacodylate; one each 
of water; 25%, 50%, 70%, 80%, 90%, 96% ethanol; and 3 three changes of 100% ethanol with each step 
10 minutes at room temperature. Samples were dried completely in the critical point dryer (Leica EM 
CPD300) and mounted on stubs (Agar Scientific) with 12 mm carbon tabs (Agar Scientific). They were 
then coated at 100 mA for 30 seconds using an EMITECH K575X sputter coater. Surface details were 
imaged using a Quanta 200 FEI field emission scanning electron microscope. 
Mechanical Testing 
Samples were analyzed for mechanical properties with pneumatic grips and a 100 N load cell on an 
Instron 3343B machine. Crosshead speed was 10 mm/min. Samples were measured for tensile stress at 
break and Young’s Modulus using Bluehill software (Instron). 
In vivo implantation of the multilayered decellularized-freeze-dried amnion 
Two three to four weeks-old female Landrace pigs of 10-15 kg were employed in this study. No mortality 
was recorded. Animals were treated in accordance with the “Guide for the Care and Use of Laboratory 
Animals” published by the National Institutes of Health in 1996 and conforming to the “Animals 
(Scientific Procedures) Act” published in 1986. Surgical procedures were performed under general 
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anaesthesia and neuromuscular blockade (Pancuronium Bromide, 2 mg/ml). Anaesthesia was induced 
by intramuscular injection of 15 mg/kg Ketamine, 0.4 mg/kg Midazolam and 5 mg/kg Dexmedetomidine 
and then maintained with inhalation of 1-2% Isoflurane. A left postero-lateral thoracotomy was 
performed and a- patches of different multilayered freeze-dried amnions were was inserted in the Left 
Pulmonary Arteries. Both animals were successfully recovered from the surgical procedures and with 
intensevely monitored ing for 24 hours. Analgesic and antibiotics were administered according to the 
needs. A combination of 10 mg/kg Paracetamol, 0.2 mg/kg Morphine, 20 mg/kg Cefuroxime and 0.4 
mg/kg Meloxicam were regularly administered intravenously during this period. The animals were 
monitored with a two-dimensional Doppler Echocardiography (VividQ, GE Healthcare) prior the surgery, 
immediately after the surgery and after 2.5 months in order to assess the LPA patency and blood flow at 
the level of the patch. After 2.5 months of follow up, pigs were euthanized with an intravenous injection 
of 150 mg/kg Euthatal. The and pulmonary arteries were dissected from the heart and then fixed in 4% 
PFA or fresh-frozen in liquid nitrogen. 
Statistical Tests 
Statistical testing was carried out with t-test or one-way ANOVA with Tukey post-hoc testing as 
appropriate, using R.  A value of p < 0.05 was considered statistically significant.  
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RESULTS 
Amnion dissection and composition 
Human placenta was collected, dissected, and cleaned to isolate the control amniotic membrane (AM) 
(Figure 1 a). The native epithelial cell layer had a cobblestone-like morphology, which was observed on 
the surface of the amnion using scanning electron microscopy (Figure 1 b). Histological characterization 
was performed using H&E and EVG staining. H&E showed a single layer of epithelial cells on the surface 
of the membrane (Figure 1 c) while EVG indicated a collagen matrix (Figure 1 d).  
The surface of the control non-processed amnion does not allow survival and growth of 
seeded MSCs  
Thymus derived mesenchymal stem cells were isolated and seeded on the surface of the AM. Cell 
viability staining demonstrated the lack of viable cells (green Calcein fluorescence). Numerous nuclei 
were observed on the surface; however, all were positive for Ethidium III (red) indicating cell death of 
the amnion’s epithelial cells as well as seeded cells. There was no observed positive calcein (green) 
staining for viable seeded cells, showing that MSCs did not survive on the matrix, due either the lack of 
adherence because of the presence of residual epithelial cells or perhaps the presence of factors 
released by the dying native AM cells that triggered MSC cell death (Figure 1 e). The scanning electron 
micrographs still showed a similar cobblestone-like morphology, but the epithelial cells appeared 
damaged; smooth, elongated MSCs were not observed (Figure 1 f). H&E cross-sections of AM-seeded 
grafts illustrated the epithelial cells on the surface of the AM but no additional cells (Figure 1 g). 
Collagens were intact as shown by EVG however, no new collagens produced by seeded cells were 
visible (Figure 1 h). In summary, the seeded MSCs did not adhere or survive on the surface of the AM. 
The latter only showed dead epithelial cells on the surface.  
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Trypsin decellularization completely removed epithelial cells and allowed for MSC adherence 
and survival and growth 
Trypsin decellularized amnion (d-AM) was stained with viability stain and H&E to verify removal of 
cellular components (Figure 2 a , b). No nuclear stain was detected. Furthermore, the epithelial cells 
were no longer visible on the surface of the matrix confirming successful decellularization with no visible 
cells or cell fragments (Figure 2 a). EVG demonstrated no disruption to the matrix following treatment; 
the collagens were preserved (Figure 2 a c ). Extracellular matrix fibers made up the surface of the 
matrix, as visualized by scanning electron micrographs (Figure 2 a d ). MSCs seeded on the surface of the 
decellularized matrix were viable (Figure 2 a e ). The elongated structure of the cells indicated the 
survival of the MSCs. Nuclei were observed on the surface of cross-sections H&E images, though in small 
numbers (Figure 2 a f, arrows). EVG showed an intact collagen matrix though with a small amount of 
loose collagen that could potentially be made by seeded cells deposition (Figure 2 a g ).  Surface 
micrographs illustrate elongated MSCs on the surface of the d-AM, with a few extracellular matrix fibers 
still visible between the cells (Figure 2 a h ).  
Preservation of the Amnion as a single and multi-layered structure resulted in better growth 
of seeded cells 
For long-term preservation of the matrix, the d-AM was freeze-dried as a single or a multi-layer. Single 
layer decellularized freeze-dried amnion (d-AM-fd-single) and multilayer decellularized freeze-dried 
amnion (d-AM-fd-multi) produced a paper-like structure (Figure 2 b i & q, respectively). H&E staining 
again illustrated no residual cellular material in d-AM-fd-single (Figure 2 b j ) while EVG demonstrated 
that the collagens became more compact (Figure 2 b k ). The compact collagen fibers of the extracellular 
matrix are visible in the scanning electron micrograph (Figure 2 b l ).  
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Cell survival was then tested on the d-AM-fd-single seeded with MSCs. After seven days in culture, 
viability staining showed elongated viable MSCs (Figure 2 c m ). This layer of cells is also seen in the 
cross-section of the H&E (Figure 2 c n ). Loose and the production of new collagens are is shown in the 
EVG (Figure 2 c o ). The scanning electron micrographs show confluent MSCs layer on the surface of the 
preserved matrix (Figure 2 c p ). 
For improving the ease of handling and strength, the material was then layered (d-AM-fd-multi) (Figure 
2 b q ). The d-AM-fd-multi had no residual nuclear material, as shown by H&E (Figure 2 b r ). EVG 
showed the collagens were undamaged but again became far more compact (Figure 2 b s ). Surface 
morphology indicated extracellular matrix fibers much the same as after decellularization (Figure 2 b t ). 
These results indicate that the matrix could be preserved and handled by layering and freeze-drying.  
d-AM-fd-multi was then tested for seeded cell survival. Cell viability indicated extensive cell population 
after one week in culture (Figure 2 c u ). This was further confirmed by H&E staining which showed 2-3 
multiple cells layer on the surface of the d-AM-fd-multi (Figure 2 c v ). The EVG demonstrated loose 
moderate new collagen production with pink fibers above the compact layers of amnion suggesting that 
this collagen could be newly made by the seeded cells (Figure 2 c w ). The cells on the surface in the 
scanning electron micrographs were compact and extracellular matrix fibers were no longer visible 
(Figure 2 c x ). The cell population growth was more robust on the freeze-dried matrixes (d-AM-fd-
single, d-AM-fd-multi) was as good (if not slightly better in case of d-AM-fd-multi) as growth than on wet 
decellularized amnion (d-AM) that was not freeze-dried.  
Quantification of Cell Survival on the Surface of the Decellularized Amnion  
Control amnion was freeze-dried (AM-fd) and rehydrated to be directly comparable to decellularized d-
AM-fd-single-seeded and d-AM-fd-multi-seeded. The cell survival and viability of the MSCs on the 
surface of the AM-fd was compared to d-AM-fd-single and d-AM-fd-multi (Figure 3). Cell viability images 
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were counted for the number of green, viable cells. Representative AM-fd-seeded (Figure 3 a), d-AM-fd-
single seeded (Figure 3 b), and d-AM-fd-multi-seeded (Figure 3 c) images show fewer viable cells on the 
dry-AM-seeded as compared to the d-AM-fd-single-seeded and d-AM-fd-multi-seeded. The data 
demonstrated significantly higher cell viability on the surface of the d-AM-fd-single-seeded (430.7 ± 32.3 
cells/mm2, n=3, technical triplicate) and d-AM-fd-multi-seeded (543.4 ± 70.5 cells/mm2, n=7, technical 
triplicate) than on the AM-fd-seeded (168.4 ± 35.8 cells/mm2, n=6, technical quadruplet; p=0.023 and 
p<0.001 respectively, Figure 3 d). There was no significant difference between the d-AM-fd-single and d-
AM-fd-multi-seeded (p=0.45, one-way ANOVA, Tukey post-hoc testing).  
Mechanical Strength of the Amnion  
The uniaxial ultimate tensile strength stress (UTS) and Young’s Modulus were calculated to determine 
the strength and elasticity of the different engineered amnion constructs (Figure 4). Amnion was 
measured and pulled to break point to determine the UTS ultimate tensile strength (Figure 4 a). The 
native, AM, was compared to the d-AM, the d-AM-fd-single, the d-AM-fd-multi, and the d-AM-fd-single 
and d-AM-fd-multi which had been seeded with MSCs and was in culture for 7 days (d-AM-fd-single-
seeded and d-AM-fd-multi-seeded). AM (1.94 ± 0.20 MPa), d-AM (1.98 ± 0.27 MPa), d-AM-fd-single 
(2.47 ± 0.24 MPa) and d-AM-fd-single-seeded (1.17 ± 0.19 MPa) had the lowest UTS with no significant 
difference in values. The d-AM-fd-multi (7.33 ± 1.15 MPa) and the d-AM-fd-multi-seeded (6.49 ± 1.22 
MPa) had significantly higher UTS than AM (p < 0.0001; p = 0.004), d-AM (p < 0.0001; p = 0.011), d-AM-
fd-single (p < 0.0001; p = 0.021), and d-AM-fd-single-seeded (p < 0.0001; p = 0.0126) respectively. No 
significant difference in UTS was observed when comparing the unseeded d-AM-fd-multi and d-AM-fd-
multi-seeded (p = 0.96). Young’s Modulus for the different materials were also calculated (Figure 4 b). 
The d-AM-fd-multi had the highest Young’s Modulus (116.4 ± 22.2 MPa) and was significantly different 
to Young’s Modulus of AM (28.0 ± 2.8; p < 0.0001), d-AM (36.1 ± 5.6; p = 0.00044), d-AM-fd-single (46.9 
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± 5.2; p = 0.00077), and d-AM-fd-single-seeded (21.3 ± 4.1; p = 0.0033). There was no significant 
difference between the d-AM-fd-multi and the d-AM-fd-multi-seeded (77.1 ± 14.3) and no other 
significant differences were noted in the other comparisons. All the tested materials had UTS and 
Young’s modulus values higher than those of native left pulmonary artery (UTS= 0.46MPa, Young’s 
modulus=1.40MPa).   
 d-AM-fd-multi supports cell survival growth of other cell types 
MSCs isolated from human umbilical cord blood (hUCB-MSCs) represent another population of cells for 
tissue engineering applied to congenital heart defect corrective surgery. These cells were expanded and 
seeded on the surface of the d-AM-fd-multi matrix. The hUCB-MSCs survived on the matrix and 
proliferated as demonstrated by viability staining (Figure 5 a) and H&E stainings (Figure 5 a). The seeded 
cells began to produce their own extracellular matrix (Figure 5 c) and completely covered the surface of 
the material as shown by SEM scanning electron micrographs (Figure 5a d). Human umbilical vein 
endothelial cells (hUVECs), characterized with von-Willebrand Factor (VWF) and CD31 staining 
(Supplement 1) were also able to survive on the matrix (Figure 5a  e) and created a sparse cell layer on 
the surface of the material as shown by H&E and SEM (Figure 5a f, h) and collagen layer (Figure 5 g). 
Smooth muscle cells offer a potential for vascular tissue engineering. Smooth muscle cells isolated from 
umbilical artery were characterized with smooth muscle actin (SMA), calponin, and myosin heavy chain 
(Supplement 1) then seeded on the surface of the d-AM-fd-multi. These smooth muscle cells survived 
(Figure 5i) and covered populated the matrix as shown by live cells staining , H&E and SEM (Figure 5b j, 
l) and created a collagen layer (Figure 5 k). Cardiac myocytes are another important cell type for 
congenital heart defect repair. and were characterized with connexin-43 and desmin staining 
(Supplement 1). Seeded cardiac myocytes survived and covered on the surface of the matrix as shown 
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by live cells staining , H&E and SEM (Figure 5b m). and created a cell layer (Figure 5 n, p). These cells 
also began to produce collagens (Figure 5 o).  
Proof-of-concept: d-AM-fd-multi shows in vivo integration and regeneration of vascular tissue  
In order to assess the in vivo biocompatibility of the developed multilayered freeze-dried amnion-
scaffold, a piglet model of left pulmonary artery (LPA) grafting was used (Figure 6 a). A small cut was 
made in the left pulmonary arteries of two piglets and two different the d-AM-fd-multi constructs were 
was inserted. Immediately after the surgery (Figure 6 b) and at 2.5 months post-operatively the LPA was 
patent with no stenosis or rupture (Figure 6 d). Macroscopic inspection of the graft after explantation 
demonstrated smooth luminal surface with no sign of thrombosis and tissue degradation (Figure 6 c). 
The blood velocity through the LPA, assessed by Doppler, showed maximum values less than 2.5m/s 
indicating normal blood flow. These results were similar to the blood flow through the LPA immediately 
prior to surgery (Figure 6 d). Histological assessment of the graft demonstrated extensive nucleation 
throughout its structure (Figure 6 e). Graft thickness resembled the neighboring native LPA, although 
not quite as thick (Figure 6 e). Histological assessment of inflammation in the graft showed no 
inflammatory cells within the newly formed tissue and away from sutures (Figure 6 f). However 
inflammatory cells, mainly lymphocytes and granulocytes, were present near the sutures (Figure 6 f). 
The presence of Inflammatory cells near sutures is common following cardiovascular surgery. The inner 
side of the graft exhibited a newly-formed organized endothelial cells layer as shown by SEM and cross 
sections isolectin immuno staining and scanning electron microscopy (Figure 6 g, h f,). The 
immuohistochemical analysis of graft cross-sections demonstrated an organized multilayer of smooth 
muscle cells comparable to the native left pulmonary artery as illustrated by alpha-smooth muscle actin, 
smooth muscle myosin heavy chain, and calponin staining indicating a vessel-like phenotype (Figure 6 h 
g ). Finally, new vessels (vasa vasorum) were observed in the adventitia of the graft indicating neo-
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vascularization that is crucial for oxygen and nutrients supply to the graft (Figure 6 i e ).  These results 
provide evidence of the suitability of our amnion-derived construct for in vivo use and particularly for 
vascular repair application. 
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DISCUSSION 
 Amniotic membrane has been used for over a century now. Its use was warranted by its easy 
and wide availability as well as its anti-microbial and anti-inflammatory properties. Here we developed a 
method that produced an amnion-derived construct that is biocompatible and strong enough for 
cardiovascular application. Our adopted strategy to decellularize then freeze-dry the amniotic 
membrane improved the viability of the seeded cells as compared to non-freeze-dried non-
decellularized material and offered a method of preservation and storage that is critical for an “off-the-
shelf” clinical product.  Additionally, layering the decellularized amnion, during the freeze-drying 
process, created a 4-ply construct with significantly improved tensile strength and elasticity that made it 
possible to use in preclinical reconstructive heart surgery.  
 Using our amnion-derived graft as a patch inserted in the left pulmonary artery of a piglet model 
demonstrated clear in vivo suitability. The grafted LPA was patent and exhibited normal blood flow up to 
2.5 months post-operatively. Additionally, the explanted graft displayed a newly formed endothelium in 
the intima, a and smooth muscle cell-rich medial layer and an adventitia containing new vasa vasorum.  
Using preserved human amnion with thymus-derived MSCs, a completely autologous graft could be 
constructed for use in corrective heart surgery for congenital heart defect patients. 
 The observed limited cell growth on the surface of native amnion led us, like others [28], to use 
decellularization as a way to improve cell viability and growth on this material. Our data demonstrated 
the advantage of decellularization for mesenchymal stem cells’ growth on decellularized amnion. Similar 
results were obtained when seeding differentiated fibroblasts on decellularized and non-decellularized 
amnion [28]. Another advantage of decellularization of the amnion is to reduce immune response in the 
recipient if used in an allogeneic manner.  
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 A variety of techniques have been used to decellularize the amnion [15], [24], [26], [28]. We 
optimized a trypsin-EDTA, nuclease decellularization protocol that eliminated cell and nuclear materials 
from the amnion. While, other groups have used their amnion material for body surface repair like foot 
ulceration repair[36], [37], lower eyelid repair[16], and fistula reconstruction[15], we have focused on 
an internal cardiovascular application for our developed amnion based bioscaffold. 
 For cardiovascular reconstructive surgery, porcine materials have commonly been used for 
cardiovascular repair because of their wide availability and good mechanical properties. 
Decellularization is frequently used to remove porcine cells’ remains that could trigger an immune 
response in the human recipient[38]–[40]. When decellularization is incomplete, it can result in 
rejection, in the recipient patient, due to the galactose-α1-3galactose (α-gal) epitope present on non-
human mammalian cells[39], [41]. The human amnion offers an alternative better solution for some 
applications with the advantage that as it obviously doesn’t contain the α-gal epitope that could be 
responsible for triggering the immune response.  Additionally, using a patient’s own autologous tissue 
could represent a further improved solution as it prevents other potential allogeneic immune response. 
For these reasons decellularized amnion represent a good safer alternative to non-human tissue-derived 
scaffolds.  
 This is the first study, to our knowledge, where the decellularized amniotic membrane has been 
prepared by preserving layered tissue, tested for cell seeding to form a tissue engineered construct, and 
finally tested for biocompatibility, feasibility and safety in an in vivo vascular repair model. The pig 
model is an ideal organism for in vivo testing of cardiovascular grafts because of its rapid growth 
potential and cardiovascular anatomy similar to human. Preservation of the matrix allows for an ‘off-
the-shelf’ solution that can be easily transported and used. It also results in improved cell survival 
compared to control dehydrated matrix. Our developed protocol is scalable in a setting where amnion 
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harvest is carried out systematically with a streamlined ethical approval. However, scalability wouldn’t 
be an issue for using the material in an autologous manner where a patient’s own amnion and stem cells 
will be used for producing a tissue engineered grafts.  
 EpiFix is a commercially available dehydrated amnion, equivalent to our control dehydrated 
matrix. The manufacturer suggests that keeping the amniotic membrane intact (non-decellularized) 
would help preserve the cytokines useful  for regenerating damaged tissue[42]. In our in vitro system, 
cell adherence and viability were very poor when MSCs were seeded on non-decellularized amnion. 
They improved dramatically when MSCs were seeded on decellularized material. These results question 
the advantage of not decellularizing the amniotic membrane. Furthermore, our in vivo experiment using 
decellularized bioscaffold showed infiltration of endothelial cells in the intima and smooth muscle cells 
in the media of the graft. Cell infiltration is a crucial process for tissue regeneration and decellularizing 
the amnion seems to be compatible with this process. In support of our results, it has been reported 
that when non-decellularized amnion was applied to ischemic rat hearts, no cell infiltrated was observed 
after 90 days in vivo[43]. Other in vivo work using non-decellularized amnion has shown inflammatory 
infiltrate[10], [20]. Decellularization may have removed cytokines from the amnion but the remaining 
extracellular matrix seems to sufficiently support cell infiltration and regeneration in vivo. Additionally, 
seeding MSCs on the decellularized amnion should further improve the regenerative capacity of the 
tissue engineered graft.  
 Consistent with previous findings, no significant difference in tensile strength was found 
following decellularization[44]. We showed, as it has previously been demonstrated, that the collagens 
and extracellular matrix proteins in the extracellular matrix are not damaged by the decellularization 
process[27]. The strength of the amnion was not compromised when decellularized or after drying for 
preservation. Furthermore, its tensile strength improved significantly when it was dried and layered. 
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This strength was important for in vivo implantation in a vessel position. After 2.5 months, the preserved 
amnion-derived graft was still intact and able to withstand the in vivo blood pressure. Further, it 
integrated well within the surrounding left pulmonary artery tissue and displayed a typical vessel-like 
structure composed of intima, media and adventitia. Other natural materials, such as decellularized 
carotid arteries and small intestine submucosa extracellular matrix, have shown similar results. When 
seeded and implanted in vivo, the grafts displayed an inner luminal layer, a medial smooth muscle layer, 
and some adventitia [32], [45]. Similar results were obtained by using synthetic scaffolds seeded with 
bone marrow mononuclear cells[46]. 
 Babies born with heart defects usually need surgery within the first six months of life and using 
reconstructive materials with growth and remodeling capacity, would reduce the number of surgeries 
the child has to endure. The growth potential of our developed construct remains to be tested in further 
investigations. However, our proof of concept in vivo study demonstrates a remodeling potential for this 
material. While the non-anti-microbial and anti-inflammatory properties[17], [18] of our amnion based-
construct warrant potential allogeneic use, these properties could be further improved by potentially 
using the patient’s own amnion collected at birth (autologous use).  
In conclusion, we successfully produced a multi-layered scaffold with biomechanical properties and 
biocompatibility suitable for in vivo vascular implantation. Our approach, not only, offers an allogeneic 
‘off-the-shelf’ solution for clinical use, but it also provides the possibility of personalized medicine by 
using a patient’s own amnion and stem cells for the production of a tissue engineered grafts for 
reconstructive heart surgery.  
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FIGURE LEGENDS 
Figure 1. MSCs seeded on native human amnion do not survive on the nonviable epithelial cell 
layer. (a) Human amnion (AM) dissected from the fetal side of the placenta and PBS washed. (b) 
Surface morphology of control amnion using scanning electron microscopy (representative 
images, n=4, bar=100 µm). (c) H&E and (d) EVG stained amnion showing a layer of native 
epithelial cells (black arrows) on the surface with a collagen (white arrows) matrix (bar 50=µm) 
(representative images, n=4, bar=50µm 12 samples collected). (e) Viability testing showed dead 
epithelial cells (Ethidium III, red) and only one viable cell (Calcein, green) (Hoerscht, blue) 
(representative images, n=4, bar=50 µm). (f) SEM indicated the epithelial cells were damaged as 
the cobblestone morphology was altered. There were no visible seeded MSCs (representative 
images, n=4, scale bar=100 µm). (g) Representative image of epithelial cells still visible on the 
surface of the H&E staining with no additional nuclei or proliferation (representative images, 
n=4, bar=50 µm). (h) EVG demonstrates AM’s that no new collagens contents are produced 
(representative images, n=4, bar=50 µm).  
 
Figure 2. (a) Cell viability, H&E, EVG and SEM of decellularized AM and decellularized AM-
seeded with T-MSCs. Ethidium and calcein viability stain shows no residual live or dead 
epithelial cells visible after decellularization. Viability staining shows MSCs seeded on the 
surface of the decellularized amnion are sparse but viable (representative images, n=5, bars=50 
µm). H&E and EVG of the decellularized AM demonstrates no remaining nuclear material or 
damage to collagens following decellularization (representative images, n=5, bars=50 µm). H&E 
of the decellularized AM-seeded with T-MSCs shows a thin layer of cells on the surface of the 
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decellularized AM (black arrows). EVG of the same material shows intact collagens (white 
arrows). SEM shows the fibers on the surface of the decellularized AM without epithelial cells. 
SEM of the decellularized AM-seeded with T-MSCs shows cells covering the decellularized AM 
fibers (representative images, n=5, bars=100 µm).  
(b) Macroscopic view, H&E, EVG and SEM of decellularized single-layered dried AM and 
decellularized multi-layered dried AM. The macroscopic view shows images of the single-
layered and multi-layered decellularized AM dried for preservation. Cross sections of H&E show 
no residual nuclear material on both single and multi-layered materials. H&E also shows one 
layer of AM in the single-layered material and four layers of AM in the multi-layered construct 
(representative images, n=5, bars=50 µm). EVG staining shows a compact set of collagens with 
no damage in the single- and multi-layered materials (representative images, n=5, bars=50 µm). 
SEM demonstrates the decellularized surface topography of the single- and multi-layered 
materials (representative images, n=5, bar=100 µm).  
(c) Cell viability, H&E, EVG and SEM of decellularized single- and multi-layered dried AM (d-AM-
fd-single, d-AM-fd-multi) seeded with T-MSCs. Live/dead staining demonstrates mainly viable 
cells on the surface of d-AM-fd-single seeded and d-AM-fd-multi-seeded (representative 
images, n=5, bars=50 µm). Cross sections of H&E show a thin layer of cells on the surface of the 
d-AM-fd-single seeded (black arrows) and a thicker layer of cells on the surface of the d-AM-fd-
multi-seeded (black arrows, representative images, n=5, bars=50 µm). EVG staining shows the 
compact set of collagens with some loose collagens in the single- and multi-layered materials. 
The loose collagens could possibly be newly formed by the seeded cells (white arrows, 
representative images, n=5, bars=50 µm). SEM shows the topography of the seeded cells on the 
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surface of d-AM-fd-single-seeded and d-AM-fd-multi-seeded (representative images, n=5, 
bars=100 µm). 
 
Figure 3. Quantification of improved cell viability on the surface of dried decellularized matrix. 
Cell viability staining indicated that the dried native amnion (a, AM-fd-seeded) seeded with cells 
on the surface had very few viable cells while the dried decellularized matrix (b, d-AM-fd-single-
seeded) and multilayered decellularized dried matrix (c, d-AM-fd-multi-seeded) seeded with 
cells exhibited more viable cells (bars=50µm). (d) Quantification of MSC survival on the AM-fd-
seeded versus the d-AM-fd-single-seeded (p=0.023) and d-AM-fd-multi-seeded (p<0.001) shows 
significantly higher cell survival on the surface of the decellularized freeze-dried tissue (AM-fd-
seeded n= 6, d-AM-fd-single-seeded n=3, d-AM-fd-multi-seeded n=7; all technical triplicate).  
 
Figure 4. Ultimate tensile strength and Young’s Modulus of the amnion. Native (AM, n=4), 
decellularized (d-AM, n=4), single layer decellularized dried and seeded (d-AM-fd-single, n=4; d-
AM-fd-single-seeded, n=4, respectively), multi-layered decellularized dried (d-AM-fd-multi, n=4) 
and d-AM-fd-multi-seeded (n=4) cultured for 7 days were compared for ultimate tensile 
strength tensile stress at maximum load and Young’s Modulus. (a) The d-AM-fd-multi and d-
AM-fd-multi-seeded were significantly stronger than the AM (p < 0.0001; p = 0.004), the d-AM 
(p < 0.0001; p = 0.011), the d-AM-fd-single (p < 0.0001; p = 0.021), and the d-AM-fd-single-
seeded (p < 0.0001; p = 0.0126) respectively. There was no significant difference between the 
unseeded d-AM-fd-multi and d-AM-fd-multi-seeded (p = 0.96). (b) d-AM-fd-multi was 
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significantly less more elastic than the AM (p < 0.0001), dAM (p = 0.00044), d-AM-fd-signle (p = 
0.00077), and d-AM-fd-single seeded (p = 0.0033). 
 
Figure 5. d-AM-fd-multi was able to support the cell growth of different multiple cell types 
suitable for cardiovascular tissue engineering. Human umbilical cord blood mesenchymal stem 
cells (a, hUCB-MSCs), human umbilical vein endothelial cells (a, hUVECs), human umbilical 
artery smooth muscle cells (b), and cardiac myocytes (b) were all able to adhere and survive on 
the surface of the d-AM-fd-multi. A layer of cells (black arrows) was visible on the surface of the 
matrix as demonstrated by H&E (a, b). EVG (a, b) staining shows a compact set of collagens with 
some loose collagens (white arrows) that could possibly be newly formed by the seeded cells 
(representative images, n=4, bars=50 µm) and (c, g, k, o) began to produce their own 
extracellular matrix (white arrows) (bars=50 um). SEM (a, b) shows the topography of the 
seeded cells on the surface of d-AM-fd-multi Surface morphology showed that all cell types 
were adhering to the matrix (representative images, n=4, bars=100 µm).  
 
Figure 6. d-AM-fd-multi implanted into the pig model produced a viable graft. (a) d-AM-fd-multi 
was implanted into the left pulmonary artery (LPA) of the piglet model. (b) Image of the 
implanted graft. Graft supported blood flow after implantation in the left pulmonary artery. (c) 
Following 2.5 months in vivo, explanted graft had integrated within the surrounding tissue. (d) 
Patent Blood flowed through the LPA with normal blood velocity shown by echocardiograms 
and Dopplers at the time of surgery, immediately post-surgery, and 2.5 months after surgery. 
(e) H&E and EVG of explanted graft compared to native left pulmonary artery demonstrate 
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extensive nucleation cell infiltrate and collagen production (representative images, n=2, 
bars=1000 µm). (f) Cross sections H&E of graft away from suture, graft close to suture and 
native left pulmonary artery (representative images, n=2, bars=50µm).   
 
(g) The native left pulmonary artery and implanted graft show a similar endothelial lining on the 
surface of the inner side indicated by SEM (bars=100µm). (h) Fluorescent staining of the graft 
cross sections Immunohistochemistry indicates that the cells on the inner side are endothelial 
cells (iso, green). It also shows smooth muscle cell markers (aSMA, smMYH and CNN in red, red 
and green respectively) throughout the media (aSMA (red), smMYH (red), and CNN(green)) 
(representative images, n=2, bars= 50µm). (i) Cross sections of H&E (bar=50µm) and 
fluorescent staining (bar=100µm) of the graft adventitia showing the vasa vasorum 
(representative images, n=2). 
 
Supplementary Figure 1. Morphology and characterization of cardiac myocytes, hUVECs, and 
smooth muscle cells. Cardiac myocytes from Promo Cell were stained with cardiac markers, 
Conn-43 and Desmin and were positive for both (red). hUVECs were stained for endothelial 
markers VWF (green) and CD31 (red) and were positive for both. Smooth muscle cells were 
stained for smooth muscle markers SMA (green), calponin (green) and myosin heavy chain (red) 
and were positive for all three (bars=50 um).  
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Fig6g-i  
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